Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ingevity (NGVT) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Ingevity (NGVT) over the last 11 years, with Q3 2025 value amounting to $11.9 million.

  • Ingevity's Capital Expenditures fell 3388.89% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.0 million, marking a year-over-year decrease of 2796.09%. This contributed to the annual value of $77.6 million for FY2024, which is 2932.6% down from last year.
  • Per Ingevity's latest filing, its Capital Expenditures stood at $11.9 million for Q3 2025, which was down 3388.89% from $12.2 million recorded in Q2 2025.
  • Ingevity's Capital Expenditures' 5-year high stood at $49.2 million during Q4 2022, with a 5-year trough of $10.0 million in Q1 2025.
  • In the last 5 years, Ingevity's Capital Expenditures had a median value of $24.9 million in 2024 and averaged $24.6 million.
  • As far as peak fluctuations go, Ingevity's Capital Expenditures skyrocketed by 6235.29% in 2022, and later plummeted by 4626.87% in 2024.
  • Over the past 5 years, Ingevity's Capital Expenditures (Quarter) stood at $37.4 million in 2021, then soared by 31.55% to $49.2 million in 2022, then plummeted by 40.65% to $29.2 million in 2023, then fell by 14.73% to $24.9 million in 2024, then tumbled by 52.21% to $11.9 million in 2025.
  • Its Capital Expenditures was $11.9 million in Q3 2025, compared to $12.2 million in Q2 2025 and $10.0 million in Q1 2025.